NCT01174160 - A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4) | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

September 30, 2012

Study Completion Date

October 31, 2012

Conditions

Atrial Fibrillation

Interventions

DRUG

vernakalant hydrochloride

Patients will receive a 3 mg/kg infusion of vernakalant hydrochloride. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of 2 mg/kg vernakalant hydrochloride will be administered.

DRUG

Placebo to vernakalent hydrochloride

Patients will receive an infusion of placebo. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of placebo will be administered.